Market Overview

MEI Pharma to Release 2018 Fiscal Year End Financial Results and Provide Corporate Update on August 30, 2018

Share:

MEI Pharma to Release 2018 Fiscal Year End Financial Results and Provide Corporate Update on August 30, 2018

PR Newswire

SAN DIEGO, Aug. 23, 2018 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ:MEIP) a pharmaceutical company focused on leveraging its extensive development and oncology expertise to identify and advance new therapies for cancer, today announced that the Company will release its 2018 fiscal year end financial results after the close of the U.S. financial markets on August 30, 2018. The Company will host a conference call and live webcast with the investment community to provide a corporate update the same day at 5:00 p.m. ET. 

Conference Call & Webcast Information
When: August 30, 2018, 5:00 p.m. ET
Dial-in: (866) 939-3921 (United States) or (678) 302-3550 (International)
Conference ID: 47469059

Please join the conference call at least 10 minutes early to register. You can access the live webcast under the investor relations section of MEI's website at: www.meipharma.com. A replay of the conference call will be archived under events and webcasts for at least 30 days after the call.

About MEI Pharma
MEI Pharma, Inc. (NASDAQ:MEIP) is a San Diego-based pharmaceutical company focused on leveraging its extensive development and oncology expertise to identify and advance new therapies for cancer. The Company's portfolio of drug candidates includes pracinostat, an oral HDAC inhibitor that is partnered with Helsinn Healthcare, SA. Pracinostat has been granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration for use in combination with azacitidine for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) who are unfit for intensive chemotherapy. Pracinostat is also being developed in combination with azacitidine for the treatment of patients with high and very high-risk myelodysplastic syndrome (MDS). MEI Pharma's clinical development pipeline also includes ME-401, a highly differentiated oral PI3K delta inhibitor currently in a Phase 1b study in patients with relapsed refractory follicular lymphoma or CLL, and voruciclib, an oral, selective CDK inhibitor shown to suppress MCL1, a known mechanism of resistance to BCL2 inhibitors. The Company is also developing ME-344, a novel mitochondrial inhibitor currently in an investigator-initiated study in combination with bevacizumab evaluating patients with HER2-negative breast cancer. Pracinostat, ME-401, ME-344 and voruciclib are investigational agents and are not approved for use in the U.S. For more information, please visit www.meipharma.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical studies and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

MEI Pharma Logo. (PRNewsFoto/MEI Pharma, Inc.)

 

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/mei-pharma-to-release-2018-fiscal-year-end-financial-results-and-provide-corporate-update-on-august-30-2018-300701266.html

SOURCE MEI Pharma, Inc.

View Comments and Join the Discussion!